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HMG-CoA
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lipase activities while elevating
from 25 to I00 MM.
Introduction"
Previously 2’-deoxyribonucleoside cyanoboranes and phosphate-boronated
nucleotides were shown to be hypolipidemic agents in rodents at 8
mg/kg/day ip and orally [i]. In rats the cholesterol levels of VLDL and
LDL fractions were reduced and the HDL-cholesterol content was
significantly increased with reductions of both serum cholesterol and
triglyceride levels after 14 days at 8 mg/kg/day of these boronated
deoxyribonucleosides. These boronated nucleosides and nucleotides were
shown to be safe for therapeutic use [2]. We have now expanded the
types of nucleosides with boron substitutions at different nitrogen
moieties. The current investigation is an effort to establish their
hypolipidemic activity in mice and rats at 8 mg/kg/day.
Methods:
Source of materials:
All of the compounds have previously been synthesized and the chemical
and physical characteristics reported [3-5]. All isotopes were purchased
from New England Nuclear. Substrates and co-factors were obtained from
Sigma Chemical Co. Sprague Dawley male rats were obtained from Charles
River Laboratory. CF 1 mice were obtained from Jackson Laboratory.
Animals were maintained in light cycles of 12 h at 22C. Rats were
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maintained in individual wire cages and mice were housed three/plastic
cage. Food (Agway/Prolab Animal Diet) and water were ad libitum.
Normalipidemic studies:
For structure activity studies, CF1 male mice (-28g) were administered
boronated nucleosides in 1% CMC at 8 mg/kg/day, ip. Blood samples were
obtained on days 9 and 16 between 7:30 and 8:30 a.m. Daily dosing of the
agents was between 9:00 and I0:00 a.m. The serum was obtained by
centrifuging the blood for i0 min. at 3500 . The serum cholesterol
levels were determined by a modification of the procedure Liebermann-
Burchard reaction [6]. Serum triglyceride levels were determined using a
commercial kit [Boehringer Mannheim Diagnostics]. Sprague Dawley male
rats (4230 g) were administered orally Compound 6 at 8 mg/kg/day, for
two weeks. Weekly blood samples were obtained by tail vein bleeding.
Animal weight, organ weight and food consumption effects:
Control and treated normalipidemic Sprague Dawley male rat(~230g)
weights were obtained and expressed as a percentage of the initial body
weight (week zero). Food consumption (gm/day/rat) was noted for two
weeks for control and treated rats[l].
Tissue lipid levels:
Normalipidemic Sprague Dawley male rats (.230 g) which were treated
orally for two weeks with compound 6 at 8 mg/kg/day, were sacrificed and
tissue samples of the liver, small intestinal mucosa and aorta were
removed. A 24 hr fecal sample was also obtained. A 10% homogenate in
0.25 M sucrose + 0.001M EDTA, pH 7.2, was prepared for each tissue. An
aliquot (2 ml) of the homogenate was extracted [7-8] and the number of
mg of lipid extracted was weighed. The lipid residue was taken up in
methylene chloride and the levels of cholesterol [6], triglycerides
neutral lipids[9] and phospholipids[10]were determined. Protein content
of the whole homogenate was determined [ii].
Serum lipoprotein fractions:
Normalipidemic Sprague Dawley male rats(-230g) treated for two weeks
with compounds 6 at 8 mg/kg/day, orally were anesthetized with ether and
blood (~I0 ml) was collected from the abdominal vein. Serum was
separated from whole blood by centrifugation at 3500 rpm. Aliquots of
the serum were separated into chylomicrons, VLDL, HDL and LDL by
ultracentrifugation as modified for normal rats [12, 13]. Each of the
fractions was analyzed for cholesterol, triglyceride, neutral lipids,
phospholipid and protein levels.
Enzymatic studies:
Compounds 3, 6, 13 and 14 were examined for their ability to inhibit i_n
vitro activities of hepatic enzymes involved in lipid synthesis and
metabolism. In vitro enzymatic studies were performed using 10%
homogenates of liver from normalipidemic Sprague Dawley male rats
(-230g). The liver homogenates were prepared in 0.25 M sucrose + 0.001
M (ethylenedinitrilo)tetraacetic acid [EDTA], pH 7.2. Acetyl coenzyme A
synthetase [14] and adenosine triphosphate dependent citrate lyase
activities [15] were determined spectrophotometrically at 540 nm as the
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hydroxylamate of acetyl coenzyme A formed after 20 min. at 37C.
Cholesterol-7a-hydroxylase activity was determined using [1,2-
3H] cholesterol 60 mCi/mmol 20 ], and acyl CoA cholesterol acyl
transferase [ACAT] activity was determined using [l-14C]oleic acid (56.7
mCi/mmol) [16]. Cholesterol synthesis was measured using [I-14C] acetyl
CoA (62 mCi/mmol) and a post-mitochondrial supernatant (9000 g x 20 min)
which was incubated for 60 min. at 37C [17]. The digitonide derivative
of cholesterol was isolated and counted 18 ]. Cholesterol ester
hydrolase activity was determined using 1-14C cholesterol oleate [56.6
mCi/mol] [19].
For acetyl carboxylase activity, the enzyme had to be polymerized for 30
min. at 37C and then the assay mixture containing sodium 14C_
bicarbonate (41.0 mCi/mmol) was added and incubated for 30 min. at 37C
with test drugs[20], sn-Glycerol-3-phosphate acyl transferase activity
was determined with sn-glycerol-3-phosphate [L-2-3H(N) (7.1 Ci/mmol)
with the microsomal fraction of liver homogenates. The reaction was
terminated after 60 min and the lipids were extracted with
chloroform/methanol (2 i) containing 1% HCl and counted[ 21].
Phosphatidylate phosphohydrolase activity was measured as inorganic
phosphate released over 60 min. [22]. The released inorganic phosphate
after color development with ascorbic acid and ammonium molybate was
quantitated at 820 nm. Hepatic lipoprotein lipase was determined using
glycerol-tri-14C-palmitate [64 mCi/mol] emulsified with lecithin by the
method of Chait et al. [23]. Protein content of the liver homogenates was
determined [ii].
Data denoted in Tables 1-5 represent the means + standard deviations of
each group expressed as a percentage of the control value. The
Student’s "t" test was applied between control groups and the individual
drug treatment groups using the raw data.
Results
The boronated nucleosides demonstrated potent hypolipidemic activity in
mice at 8 mg/kg/day ip. Compounds I, 3, 4, 5, 6, II, 12, 13, 14, and 15
decreased serum cholesterol levels at least 40% by day 16 [Table i].
Serum triglyceride levels were reduced greater than 30% on day 16 by
compounds 3, 7, 12, 13, 14, and 15. All of the derivatives afforded
better hypolipidemic activity than the standards clofibrate at 150
mg/kg/day or lovastatin at 8 mg/kg/day in mice.
Compound 6 was selected for further studies as being representative of
this class of derivatives. This compound reduced serum cholesterol
levels in rat 36% and serum triglyceride levels were reduced 32% on day
14 after oral administration [Table 2].
Rat tissue lipids after 14 days of drug administration were not
elevated. Aorta wall cholesterol was reduced 24% after administration of
compound 6 [Table 3]. Fecal triglycerides and phospholipids were
elevated significantly after 14 days, i.e. 104% and 50%, respectively
while cholesterol levels were reduced 24%. Small intestinal mucosa and
aorta wall triglyceride levels were reduced as was aorta wall
phospholipids and protein content.
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Figure 1 Structures of Boronated Nucleosidyl
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Figure ’
Structures of Boronated Nucleosidyl
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Table I: In Vivo Hypolipidemic Activity of Cyanoborane Adducts in CF1
Male Mice at 8 mg/kg/day, ip for 16 Days.
N=6 Percent of Control (X+S.D.)
Compound Day 9 Day 16 Day 16
# Serum Serum Serum
Cholesterol Cholesterol Triglyceride
1 79+/-5 57+/-4* 72+/-4*
2 87+/-6 70+/-4* 83+/-5
3 81+/-4 60+/-3* 47+/-3*
4 59+/-5* 54+/-3* 81+/-5
5 78+/-4* 55+/-4* 73+/-3*
6 94+/-5 65+/-3* 70+/-3*
7 78+/-4* 75+/-5* 64+/-6*
8 84+/-5 75+/-4* 87+/-5
9 75+/-5* 72+/-4* 78+/-4*
I0 73+/-4* 73+/-3* 74+/-3*
II 76+/-4* 60+/-4* 70+/-4*
12 55+/-3* 46+/-3* 66+/-3*
13 49+/-4* 48+/-3* 64+/-5*
14 54+/-4* 41+/-3" 60+/-4*
15 54+/-6* 51+/-3" 56+/-3*
Control i00+/-5d i00+/-7e i00+/-6f
Lovastatinb 85+/-4 82+/-5* 86+/-7
Clofibratec 87+/-6 78+/-6* 75+/-6*
D c a 1% CMC; osed at 8 mg/kg/day; Dosed at 150 mg/kg/day;d125
serum cholesterol; e 128 mg/dL serum cholesterol; f 137 mg/dL
triglyceride; p 0.001, Student’s "t" test
mg/dL
serum
Table 2 In Vivo Hypolipidemic Activity of the Cyanoborane Adduct of
3’-Amino Dideoxythymidine(6) in Sprague-Dawley Male Rats
or 14 Days.
ol (XS.D.)
Day 7 Serum Day 14 Serum
Cholesterol Triglyceride Cholesterol Triglyceride
87+4 86+7 64+/-9* 68+6*
I00+6 f 100+4g i00+6h i00+5
85+4 91+5 82+5 86+7
91+5 82+7 62+5*
89+7 83+6 86+5 74+7*
at 8mg/kg/day Orally f
N=6 Percent of Contr
Compound Food
Consumptiona
Compound 6 100+7
Controlb 100+6
Lovastatinc
Gemfibrozild 91+5
Clofibratee
’Control 22.1_+1.3 g/day/rat; b 1% CMC; c Dosed at 8 mg/kg/day; d Dosed at
90 mg/kg/day; e Dosed at 150 mg/kg/day; f 73 mg/dL total serum cholesterol
g 75 mg/dL total serum cholesterol; h Iii mg/dL serum triglyceride
i 112 mg/dL serum triglyceride; p < 0.001, Student’s "t" test
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Table 3:In Vivo Effects of the Cyanoborane Adduct of 3’-Amino Dideoxy-
thymidine on Tissue Lipids in Sprague-Dawley Male Rats After 14 Days at
8 mg/kg/day, Orally
N=8 Percent of Control (X+S.D.)
Mg Lipid Choles- Trigly- Neutral Phospho- Protein
Extracted terol cerides Lipids lipids
Liver
Control I00 + 4a i00 + 5b i00 + 7c I00 + 6d i00 + 7e i00 + 6f
Cmp’d 6 96 _+ 6 104 _+ 6 Ii0 + 4 95 + 7 99 _+6 89 + 6
Small Intestine
Control I00 + 8g i00 + 7 h i00 + 61 i00 + 6J i00 + 6k i00 + 71
Cmp’d 6 86 _+ 5 112 + 6 81 + 7 99 _+ 7 i00 + 5 98 + 6
Aorta
Control I00 + 4m i00 + 5n I00 + 6 I00 + 5P i00 + 6q i00 + 6r
Cmp’d 6 94 + 7 76 + 5* 75 + 4* 99 _+ 7 87 + 7 84 + 7
Feces
Control I00 + 8s I00 + 6t I00 + 6u i00 + 8v I00 + 8w I00 +6x
Cmp’d 6 94 _+ 8 76 + 6* 204 + i0" 98 + 7 150 + 6* 98 + 5
concentration/ gram wet tissue:
a 50.5 mg lipid
b 9.18 mg cholesterol
c 6.37 mg triglyceride
d 15.70 mg neutral lipid
e 27.19 mg phospholipid
f 12.02 mg/protein
g 68.20 mg lipid
h 12.02 mg cholesterol
i 11.20 mg triglyceride
J 16.98 mg neutral lipid
k 20.06 mg phospholipid
1 42.0 mg protein
p0.001, Student’s "t" test
m 67.5 mg lipid
n 5.77 mg cholesterol
o 9.85 mg triglyceride
P 15.28 mg neutral lipid
q 28.8 mg phospholipid
r 11.71 mg/protein
s 11.58 mg lipid
t 2.84 mg cholesterol
u 1.86 mg triglyceride
v 3.39 mg neutral lipid
w 5.70 mg phospholipid
x 6.99 mg/protein
Rat serum lipoproteins after 14 days administration of compound 6 showed
a 24%, 20% and 12% reduction in cholesterol levels of chylomicrons, VLDL
and LDL fractions while HDL-cholesterol content was elevated 65% [Table
4]. Triglyceride content was increased in the chylomicron but lowered in
the VLDL and HDL fractions. Phospholipids were lower in the chylomicron
and VLDL fractions but was elevated in the LDL fraction. Protein
content was reduced in the chylomicron and VLDL fractions but was
elevated in the LDL and HDL fractions.
In vitro hepatic enzyme activities showed similar patterns of effects
for the four compounds tested over 60 min [Table 5]. Cytoplasmic acetyl
CoA synthetase activity was suppressed significantly by all of the
agents following a concentration dependent response. ATP-dependent
citrate lyase activity was also reduced by the compounds except by
compound 14. HMG-CoA reductase activity was suppressed moderately by
19% by compound 3 at I00 tM but compounds 13 and 14 caused greater than
50% reduction. Acyl-CoA cholesterol acyl transferase activity was
reduced 32-37% by compounds 6 and 14 and 47% by compounds 3 and 13 at
I00 tM. Cholesterol ester hydrolase activity was suppressed 37% by
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compound 6 and 62% by compound 3. Cholesterol-7-hydroxylase activity
was elevated 12-60% by the agents at I00 MM.
Acetyl-CoA carboxylase activity was elevated by compounds 3 and 13 at
all concentrations whereas compounds 6 and 14 caused only 15% reduction
at I00 tM. sn-Glycerol-3-phosphate acyl transferase activity was
essentially unaffected by the compounds. Phosphatidylate
phosphohydrolase activity was markedly reduced by compounds 3, 13 and 14
from 72% to 85% whereas compound 6 caused only 18% reduction. Hepatic
lipoprotein lipase activity was reduced 47-48% by compounds 3 and 13 and
24% by compound 6 but the activity was elevated 127% by compound 14 at
I00 M.
Discussion
The boronated nucleosides were potent hypolipidemic agents in rodents at
8 mg/kg/day both by po and ip administration. The N boronated guanosine
derivative 3 as well as 3’-aminocyanoborane dideoxythymidine 6, the
Table 4: In Vivo Effects of Cyanoborane Adduct of 3’-Amino Dideoxy-
thymidine 6 on the Lipid Content of Serum Lipoproteins in Sprague Dawley
Male Rats After 14 Days at 8mg/kg/day, Orally
N=8 Percent of Control (X+/-S.D.)
Cholesterol Triglycerides Neutral Phospho- Protein
Lipids lipids
Chylomicron
Control 100 + 6a 100 + 7b 100 + 7c 100 + 6d 100 + 5e
Compound 6 76 Z 5* 138 Z 8* 82 Z 6 55 Z 4* 79 6
VLDL
Control i00 + 4 f I00 + 5g i00 + 7h i00 + 7 i i00 + 5J
Compound 6 80 4* 86 6 i01 6 60 5* 54 5*
LDL
Control 100 + 5k 100 + 61 100 + 6m 100 + 6n 100 + 8
Compound 6 88 4 99 7 94 6 158 8* 132 6*
HDL
Control i00 + 6P I00 + 7q I00 + 6r I00 + 7 s I00 + 6t
Compound 6 165 +/- 8* 68 5* 96 +/- 5 103 +/- 6 164 +/- 7*
per ml serum
a 337 Ng cholesterol
b 420 gg triglyceride
c 67 gg neutral lipid
d 149 gg phospholipid
e 184 gg protein
f 190 gg cholesterol
g 22 g triglyceride
h 98 gg neutral lipid
i 26 Ng phospholipid
J 50 Gg protein . p 5 0.001, Student’s "t" test
k 210 g cholesterol
1 45 gg triglyceride m
m I0 g neutral lipid
n 41 @g phospholipid
o 122 g protein
P 544 g cholesterol
q 630 gg triglyceride
r 27 Gg neutral lipid
s 153 @g phospholipid
t 657 gg protein
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Table 5". In Vitro Effects on Liver Enzyme Activities of Hypolipidemic
Nuc ieoside -cyanoboranes
N=6 Percent of Control X + S.D.)
Compound 3 Compound 6
Enzyme Control 25M 50M 100M 25M 50M 100M
Acetyl-CoA Synthetase I00+/-7a 63+/-4* 23+/-2* 7+/-1" 89+/-6 81+/-6 78+/-5*
ATP-dependent i005b 84+/-5* 765" 52+/-4* 96+/-4 916 725"
-Citrate Lyase
HMG CoA Reductase I00+/-7c 139+/-5" 136+/-4" 81+/-4" 99+/-6 I026 i085"
Acyl CoA Cholesterol- i00+/-6d 87Z5 77+/-6* 534" 865 I066 687"
-acyl Transferase
NeutralCholesterol i00+/-5e 93+/-5 46+/-4* 38+/-3* 73+/-6* 64+/-5* 63+/-6*
Ester Hydrolyase
Cholesterol-7-alpha-
hydroxylase I00+/-6 f 96+/-4 112+/-4 I125 107+/-6 128+/-6" 132+/-5"
Acyl CoA Carboxylase 1005g 3969" 2838" 2537" 886 884 85Z5
sn-Glycero-l,3- I00+/-6 h 127+/-6" 119+/-5 107+/-6 113+7 108+/-6 104+/-5
Phosphate Acyl Transfease
Phosphatidylate
Phosphohydrolase 100+59 46+4* 28+4* 17+2" 107+6 86+5 82+4*
Lipoprotein Lipase 100Z6k 66+/-5* 54Z4" 53+/-3* 997 836 74+/-6*
a 28.5 mg acetyl CoA formed/g wet tissue; b 30.5 mg citrate
hydrolyzed/g wet tissue; c 384900 dpm cholesterol formed/g wet tissue;
d 224000 dpm/mg of microsomal protein e 56436 dpm/mg wet tissue;
f 4808 dpm/mg of microsomal protein; g 537800 dpm/mg wet tissue; h
302010 dpm/mg wet tissue; i 16.7 @g Pi released/g wet tissue; J 278538
dpm/g wet tissue. P 5 0.001, Student’s "t" test
N=6
Enzyme
Percent of Control (X+S.D.)
Compound 13 Compound 14
Control 25MM 50M 100M 25MM 50MM 100M
Acetyl CoA Synthetase i00+/-7a 49+/-4* 30+/-2* 2+/-1" 805 43+/-3* 36+/-3*
ATP-dependent Citrate Lyase
I00+5b 67+5* 58+5* 55+3* 117+6 96+5 88+4
HMG CoA Reductase I00+7 c 59+5* 56+4* 45+2 58+4* 52+4* 49+4*
Acyl CoA Cholesterol
Acyl Transferase I006d 87Z6 68+/-6* 53+/-3* 785" 634" 63+/-3*
Neutral Cholesterol Ester
Hydrolase 100Z5e 139Z8 91Z6 89Z7 141Z14- 98Z5 87Z5
Cholesterol-7-alpha-
Hydroxylase 100Z6 f Iii+/-7 160Z8" 160Z7" 965 I006 1226
Acyl CoA Carboxylase 100z5g 357Z9" 299+/-9* 168Z8" I15Z6 100+/-4 855
sn-Glycero-l-3-Phosphate
Acyl Transferase 100Z6h 104+/-5 92Z6 86+/-4 94Z5 92Z5 885
Phosphatidylate
Phosphohydrolase 1005J 464" 24Z3" 152" 78Z5" 354" 283"
Lipoprotein Lipase I00+/-6k 181+/-7 49Z4- 52Z4" 1508" 190Z8- 2279"
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boronated adenosine arabinoside 13 and thymidine 5’-boranophosphate 14
demonstrated good activity in lowering both serum cholesterol and
triglyceride levels after 16 days in mice. The boronated thymidine mono
and triphosphates were very effective agents but the ribose-nucleosides
were not as potent hypolipidemic agents at this dose. Enzymatic
studies demonstrated that four of these derivatives inhibited rat
hepatic cytoplasmic acetyl-CoA synthetase markedly and ATP-dependent
citrate lyase activity moderately which would reduce acetyl-CoA
necessary for both fatty acid and cholesterol syntheses. The reduction
of HMG-CoA reductase activity, the regulatory enzyme for cholesterol
synthesis, by some of the agents should add to the overall reduction of
tissue, lipoprotein and serum cholesterol levels. The agents, 13 and
14, which demonstrated good inhibition of the activity of this enzyme
were more effective in lowering cholesterol levels than the compounds, 3
and 6, which only lowered acetyl CoA synthetase activity. All of the
agents lowered hepatic acyl-CoA cholesterol acyl transferase activity,
the enzyme responsible for cholesterol ester synthesis. Assuming that
the same inhibition occurred in the aorta wall, of this enzyme activity
by the agents then plaque growth should be reduced since their size
depends directly on the deposition of cholesterol esters. Cholesterol-
7--hydroxylase activity was elevated by the agents. This is the
regulatory enzyme for converting cholesterol to bile acids for excretion
into the bile. The lowering of triglyceride levels by the agents is
probably due to their ability to reduce the activity of phosphatidylate
phosphohydrolase, the enzyme responsible for conversion of phospholipids
to triglycerides. The reduction of hepatic lipoprotein lipase by three
of the agents would lower the removal of triglycerides from lipoproteins
for delivery to the liver or other tissues.
In vivo studies with the 3’-aminocyanoborane- dideoxythymidine showed
that rat serum cholesterol and triglyceride levels were reduced at 8
mg/kg/day and was comparable in hypolipidemic effects to lovastatin at 8
mg/kg/day and clofibrate at 150 mg/kg/day in rats.
This agent, compound 6, achieved lowering of VLDL and LDL cholesterol
content while elevating HDL cholesterol levels. Modifying this ratio is
important in choosing a hypolipidemic therapeutic agent in that VLDL and
LDL lipoprotein conduct cholesterol to peripheral tissues including the
aorta walls leading to deposition and tissue accumulation whereas HDL
conducts free cholesterol from peripheral tissue to the liver for
excretion in the bile. Hyperlipidemic patients have high VLDL and LDL
cholesterol content and low HDL-cholesterol content; thus, if a
therapeutic agent reverses this ratio this is useful clinically [24].
This compound effectively lowered aorta wall cholesterol levels after 14
days administration but there was no observable elevation in cholesterol
excretion in the feces on day 14, but triglyceride excretion and
phospholipid excretion was elevated at this time. The pharmacological
properties of these boronated nucleosides as hypolipidemic agents are
similar to those of boronated derivatives reported previously [I].
These studies demonstrate that the compound have potential as
hypolipidemic agents but further structure activity relationship studies
are need before an agent can be selected for clinical development.
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